Bristol-Myers Squibb Company (BMY)

Healthcare • Drug Manufacturers - General

Beobachten

$59,57

Price

-1,29%

Change

121,31 Mrd. $

Market Cap

P/E Ratio

Neumann-Score Stock Analysis

out of 100

Beobachten

Valuation??/100

Profitability??/100

Growth??/100

Unlock Score Details

Become a member and get access to all analyses.

Become a Member

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectab ...

CEO

Christopher S. Boerner

Employees

34.100

Country